Chemokines are mainly involved in the recruitment of leukocytes into tissues, a key feature of inflammation. Through its unique receptor CX3CR1, the chemokine CX3CL1 participates in diverse inflammatory processes including arterial atherosclerosis and cerebral or renal inflammation. Using a phage display strategy, we engineered a hCX3CL1 analog (named F1) with a modified N terminus. F1 bound specifically to cells expressing hCX3CR1 and had a K d value close to that of native CX3CL1. F1 was not a signaling molecule and did not induce chemotaxis, calcium flux, or CX3CR1 internalization. However, it potently inhibited the CX3CL1-induced calcium flux and chemotaxis in CX3CR1-expressing primary cells of human and murine origin with an IC 50 of 5-50 nM. It also efficiently inhibited the cell adhesion mediated by the CX3CL1-CX3CR1 axis. Finally, in a noninfectious murine model of peritonitis, F1 strongly inhibited macrophage accumulation. These data reveal a prototype molecule that is the first bona fide antagonist of hCX3CR1. This molecule could be used as a lead compound for the development of a novel class of antiinflammatory substances that act by inhibiting CX3CR1.
Introduction
Chemokines are a family of small, secreted proteins (typically 8 -10 kDa) that are involved in leukocyte trafficking in homeostatic and inflammatory conditions [1] . They, together with their receptors, have been identified as potential targets for modulating leukocyte migration in physiological or pathological conditions [2, 3] .
The chemokine CX3CL1 (fractalkine) is structurally distinct from other conventional chemokines, in that it exists in soluble and membrane-anchored forms [4] . Membrane-anchored CX3CL1 promotes strong selectin-and integrin-independent adhesion of leukocytes that express CX3CR1, its unique receptor. sCX3CL1, on the other hand, which is produced by the cleavage of native CX3CL1, is a potent chemoattractant [4 -6] .
As stress and inflammatory cytokines up-regulate CX3CL1 expression [7] , the CX3CR1/CX3CL1 axis has been implicated in a number of inflammatory diseases [8, 9] . The genetic ablation of mCX3CR1 leads to decreased atherogenesis but to increased brain inflammation and pain facilitation [10 -13] , to increased microglial neurotoxicity [14] , and to early AMD [15] . Moreover, the rare CX3CR1 allelic variant in humans mirrors the phenotype of CX3CR1-deficient mice and has been associated with a reduced risk of cardiovascular diseases [16 -18] and with AMD [15] . Furthermore, it has been associated with a reduced risk of inflammatory lung disorders [19, 20] , an increased risk of cerebrovascular diseases [21] , and increased survival after glioblastoma diagnosis [22] . The recruitment of CX3CR1-expressing leukocytes such as cytotoxic CD8 T cells and NK cells to glomeruli appears to be associated with glomerulonephritis [23] and lupus nephritis [24] . Finally, CX3CR1
ϩ leukocyte recruitment plays a role in rheumatoid arthritis [25] and inflammatory bowel disease [26] . Hence, CX3CR1 and CX3CL1 are promising targets for anti-inflammatory drugs, and there is a strong clinical rationale for the development of hCX3CR1 antagonists. This study was designed to identify CX3CL1 analogs with antagonistic activity on hCX3CR1. As is generally the case for chemokines [27, 28] , the N terminus of CX3CL1 plays the largest role in interaction with CX3CR1 [29] . Based on reports that N-
Phage-chemokine and library constructions
The DNA sequence coding for hCX3CL1 was amplified by PCR from pBlast-hCX3CL1 plasmid (Invivogen, San Diego, CA, USA) with NcoI-tailed forward primer 5Ј-CCGGCCATGGCCCAGCACCACGGTGTGAC and NotItailed reverse primer 5Ј-TTGTTCTGCGGCCGCGCCATTTCGAGTTAG (the recognition sites for endonuclease are underlined). The PCR product was cut and subcloned into a pHEN1 phagemid vector (kindly provided by Gregory Winter, Cambridge University, Cambridge, UK) as described previously [34] . The library of N-terminal CX3CL1 mutants was constructed by PCR mutagenesis, essentially as reported in ref. [31] with the NotI-tailed reverse primer and a degenerate upstream primer 5Ј-CCGGCCATGGCC-NNKCNANNKNNKGNCNTGNCAAAATGCAACATCACGTGC (the recognition site for NcoI is underlined; N represents any of the four bases; K represents G or T). The PCR products were cloned into phagemid pHEN1-cut NcoI-NotI and electroporated into Escherichia coli TG1. Colonies were PCRscreened before selection, and their DNA inserts were sequenced with the ABI 377 (Applied Biosystems, Perkin-Elmer, Waltham, MA, USA) automatic sequencer to check the library diversity.
Selection of CX3CR1 antagonists on living cells
The selection strategy is presented (see Fig. 1A ). A phage library of CX3CL1 mutants (10 10 CFU) was incubated directly with 5 ϫ 10 6 HEK-CX3CR1 or HEK-CCR5 cells growing in 25 cm 2 tissue-culture flasks (Becton Dickinson, Le Pont de Claix, France) at 37°C at 5% CO 2 in 5 ml supplemented DMEM medium. After 1 h, cells were washed 10 times at room temperature with 10 ml PBS and then scraped from the plate into 10 ml PBS-0.5% BSA. Cells were then pelleted and incubated for 20 min on ice in elution buffer consisting of an excess of sCX3CL1 (10 M in 100 l PBS-BSA). Cells were centrifuged (1000 g for 5 min), and supernatant was mixed with logphase E. coli TG1 for production and purification of stock phage to be used in further rounds of selection, as described previously [31] .
Phage display of chemokine domain
The purified phage chemokines were used in phage-ELISA as described [35] with the anti-hCX3CL1 polyclonal antibody (AF365, R&D Systems, Lille, France) as coating. For flow cytometry analysis, phages (10 10 CFU/ ml) were incubated at 4°C with 10 5 HEK or HEK-CX3CR1 cells, which were washed and incubated with anti-M13 antibody (Pharmacia, Saclay, France) labeled with FITC, as described previously [36] , and analyzed on FACSCalibur (BD Bioscience, Le Pont de Claix, France) with CellQuest software.
Preparation of CX3CL1 analog and chimeric Ig fusion chemokines
F1, the CX3CL1 analog, was prepared by total chemical synthesis, essentially as described previously [37] . Compound purity and integrity were verified by analytical HPLC and mass spectrometry (data not shown). Concentrations were determined by measurement of A 280 nm . The chimeric chemokine-Ig construct was prepared as described previously [38 -40] . The murine Fc␥2a fragment is mutated in the Clq-binding motif (E318, K320, K322), and the Fc␥RI-binding site (L235) [41, 42] was used to produce a noncytolytic form of F1-Ig. The DNA sequence of F1 was amplified from the phage display vector with the NotI-tailed reverse primer and a specific upstream primer encoding the hCX3CL1 signal peptide 5Ј-AAAACTGCAGCCATGGCTCCGATATCTCTGTCGTGGCTGCTCCGC-TTGGCCACCTTCTGCCATCTGAC TGTCCTGCTGGCTGGAATTCTA-GATAATGGCGTGTCA-3Ј (the recognition site for PstI is underlined). The PCR product was cloned into a pVRC vector (a generous gift from Dr. Dan Barouch, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA) as described previously [38, 40, 43] .
Low-endotoxin pVRC chemokine-Ig (5 g) and empty pBlast plasmids (1 g) were cotransfected into a CHO-S cell line (Invitrogen, Cergy-Pontoise, France) with the JetPEI TM transfection reagent, according to the manufacturer's instruction (Polyplus-Transfection SA, Illkirch, France). Transfectants were selected by adding 10 g/ml blasticidin (Invivogen Cayla, Toulouse, France) and maintained with 5 g/ml blasticidin. Highproducing clones were selected by screening supernatants for CX3CL1 by capture ELISA (hCX3CL1/fractalkine, R&D Systems). Chemokine-Ig fusion proteins from 500 to 1000 ml culture supernatant were purified through protein G columns (NUNC ProPur Kit Midi G, VWR International S.A.S., Fontenay sous Bois, France). The protein was buffer-exchanged and concentrated to a final volume of 1 mL in PBS. Chimeric protein solutions were tested by SDS-PAGE, silver-staining, and immunoblotting assays to estimate the purity of preparations. Protein concentrations in solution were determined by measurement of A 280 nm and capture ELISA before the in vivo experiments.
CX3CR1 receptor down-modulation experiments
Cells (10 5 ) were incubated for 30 min at 37°C in 100 l supplemented culture medium containing various concentrations (1-1000 nM) of chemokines. Medium alone was used as a control. Cells were washed five times with cold PBS and incubated for 30 min on ice with 50 ng anti-hCX3CR1 mAb (clone 2A9-1 PE-conjugated, MBL Clinisciences, Montrouge, France). Cells were washed twice, fixed with 4% paraformaldehyde, and analyzed with a FACSCalibur and CellQuest software. At least 10,000 events were accumulated for each sample. The percentage of surface CX3CR1 expression was calculated according to the MCF as follows: (MCF chemokine-MCFnegative control)/(MCF medium-MCF-negative control) [44] .
Competitive radioligand binding to CX3CR1
Assays were performed as described previously [16] . 
Calcium mobilization assay
Cytosolic-free calcium was measured with Fura-2/AM (Molecular Probes, Leiden, Netherlands), essentially as described [45] . Briefly, PBMC (4ϫ10 6 ) were loaded for 30 min at 37°C with 2 M Fura-2/AM and 2 M pluronic acid in 1 ml HBSS buffer supplemented with 10 mM HEPES, 0.5 mM MgCl 2 , and 1 mM CaCl 2 . Cells were centrifuged and transferred to quartz cuvettes for reading. Chemokines and chemokine-Ig fusion proteins were added to the cells at various concentrations in cuvettes thermostatically maintained at 37°C and stirred continuously. Fluorescence was monitored with a spectrofluorometer (SAFAS, Monaco) at 340 and 380 nm and measured at 510 nm.
Chemotaxis assay
Migration assays were performed in 24-transwell inserts (Corning Costar, Avon, France) with 5 m pore polycarbonate filters for human PBMC and 8 m filters for mouse MBMC or mouse peritoneal cells, which were resuspended in chemotaxis buffer (5ϫ10 5 cells in 100 l RPMI containing 0.5% BSA and 10 mM HEPES) and loaded into the top chamber. The bottom of each well was filled with 600 l prewarmed chemotaxis buffer at the indicated chemokine concentration. The plates were then incubated for 3 h at 37°C in a 5% CO 2 atmosphere. Cells that passed through the membrane were immunophenotyped by mixing fluorescent antibodies (anti-hCD45-FITC, CD8-APC, CD3-PE, or anti-mouse CD11b-FITC, Becton Dickinson) and a predetermined number of beads (Flow-Count™ fluorospheres, Beckman Coulter, Villepinte, France). After 30 min incubation on ice, beads and cells were counted on a FACSCalibur flow cytometer, and data were analyzed with CellQuest software. Results are expressed as a CI that represents the ratio of cells migrating in the presence versus the absence of chemoattractant. All conditions were run in duplicate, and results are representative of at least three independent experiments.
Adhesion assay
CX3CL1-H 6 (1 nM in 50 L/well, R&D Systems) or the purified chemokine-Ig proteins (diluted at the indicated amount) were plated overnight at 4°C on Maxisorb 96-well microtiter plates (Nunc A/S, Roskilde, Denmark) in buffer containing 25 mM Tris, pH 8, 150 mM NaCl. HEK-CX3CR1 cells loaded with carboxyfluorescein diacetate succinimidyl ester (Invitrogen) were incubated for 45 min at room temperature in the presence or absence of CX3CL1 or F1 at the indicated concentrations in plates blocked previously with 1% nonfat milk. To remove nonadherent cells, the wells were filled gently with PBS, and the microplate was placed floating upside down in PBS for 1 h before reading at 535 nm with a Fusion Universal Microplate Analyzer (Packard Bioscience, Perkin Elmer, Villebon sur Yvette, France), as described previously [46] . Experiments were performed in triplicate, and results expressed as the percentage of total adherent cells (Ϯsd).
Thioglycollate-induced peritoneal inflammation
Wild-type 6-to 10-week-old female C57BL/6 mice (Janvier, Le Genest Saint Isle, France) were injected i.p. with 1 ml 3% (wt/vol) thioglycollate (SigmaAldrich, l'Ile d'Abeau, France) and dissolved in sterile PBS and then 14 h later, with 50 g F1 or 25 g F1-Ig in 50 l PBS. Two days later, the mice were killed, and 3 ml cold PBS was injected i.p. to harvest peritoneal cells, which were then stained with anti-CD11b-PerCP, anti-Ly6G-PE, anti-7/4-FITC, and F4/80-APC (R&D Systems). At least 10 -15 ϫ 10 6 cells/mouse were counted. The local animal experimentation and ethics committee approved the experimental protocol.
Statistics
The data were analyzed and displayed with GraphPad Prism 4 (GraphPad Software, San Diego, CA, USA). Statistical comparisons used unpaired twosample t-tests; P Ͻ 0.05 was considered statistically significant.
RESULTS

Engineering the CX3CR1 antagonist
Phage particles can be endocytosed efficiently by mammalian cells in a receptor-dependent manner [47] , and phagechemokine agonists can, as we have shown, be recovered after cell lysis [31] . We made use of a modified phage display-based selection strategy with live-cell competitive elution to select preferentially for CX3CL1 variants with antagonist properties (Fig. 1A) . In this strategy, the phage library was incubated with CX3CR1-expressing cells at 37°C to allow ligand-induced internalization of agonist phage particles. Phage displaying CX3CR1 antagonists would not enter the cell and would therefore be susceptible to competitive elution with a large excess of sCX3CL1.
The hCX3CL1 chemokine domain, which consists of the first 77 residues of the mature protein, was cloned for expression by phage display. CX3CL1-phage showed detectable bind- (1) The library of phage-displayed CX3CL1 mutants is allowed to bind HEK cells stably expressing CX3CR1. The cells were incubated at 37°C to permit ligand-induced internalization of agonist phage particles, while CX3CR1 antagonists do not enter into the cell. (2) Stringent washing was used to remove nonspecifically bound phage. (3) An excess of sCX3CL1 was added to remove surface-associated phage. Eluted phages were allowed to infect E. coli, and stocks of selected phages were prepared to be used in a new round of selection (steps 1-3). (B) Phage ELISA using CX3CL1-expressing phage, phage-F1, and control phage expressing CCL5. Phage-CX3CL1 and phage-F1 bound anti-hCX3CL1 antibody. (C) Flow cytometry analysis of phage-CX3CL1, phage-F1, and phage-CCL5 on HEK wildtype (thin line) and HEK-CX3CR1 cells (bold line), as indicated. rfu, Relative fluorescence unit.
ing on anti-CX3CL1 antibody but not isotype control antibody (Fig. 1B) . Additionally, CX3CL1-phage bound to HEK cells that expressed CX3CR1 (Fig. 1C) but not to parental HEK (Fig. 1C) or CCR5-expressing cells (data not shown). CCL5-expressing phage [31] did not bind to the anti-CX3CL1 antibody (Fig. 1B) or the HEK-CX3CR1 cells (Fig. 1C) . These results show that CX3CL1-phage bound specifically to CX3CR1-expressing cells.
Based on our previous work [31] and on our evidence that CX3CL1 is expressed successfully on phage (Fig. 1) , we used PCR mutagenesis to design and express a phage library of CX3CL1 variants, where the first six residues of the CX3CL1 DNA sequence were randomized completely (positions 2 and 3) or partially (positions 1, 4, 5, and 6). As a number of chemokine analogs featuring N-terminal extensions have been reported to have antagonist activity [31, 48] , we added a oneresidue N-terminal extension (position 0) into our library design. Finally, the library of CX3CL1 mutants had the following composition: X 0 Z 1 X 2 X 3 ⌺ 4 ⌽5⌿ 6 -CX3CL1 (7-77), where X is any amino acid; Z is L, P, Q, or R; ⌺ is V, A, D, or G; ⌽ is L, M, or V; and ⌿ is S, P, T, or A ( Table 1) .
After four rounds of selection on HEK-CX3CR1 cells, comparison of the selected sequences enabled us to define a consensus sequence: I L D X G L/V A/S, where X is any amino acid (Table 1) . To ascertain whether the selection of this consensus sequence was CX3CR1-specific, we performed the same selection procedure on HEK-CCR5 cells. After two rounds of biopanning, most of the selected phage had lost the CX3CL1 gene insert (data not shown). Finally, we confirmed that a preferentially selected phage clone-ILDNGVS, henceforth called F1-bound to an immobilized anti-CX3CL1 antibody (Fig. 1B) and to CX3CR1-expressing cells (Fig. 1C) . This binding was specific: Phage-F1 did not recognize control IgG (Fig.  1B) , parental HEK (Fig. 1C) , or HEK-CCR5 (data not shown).
For further analysis, we then used chemical synthesis to produce the F1 analog as a soluble protein, corresponding to the CX3CL1 chemokine domain. In addition, we produced a recombinant fusion protein of F1 with the murine Fc fragment of Ig (F1-Ig) to generate a variant of F1 with a longer in vivo half-life (data not shown and ref. [41] ).
Characterization of F1 as CX3CR1 ligand
The binding affinity of F1 for CX3CR1 was compared with that of native CX3CL1 in a competition binding, with HEK-CX3CR1 cells and [
125 I]-CX3CL1 as a tracer (Fig. 2A) . The F1 analog interacted with CX3CR1, although with a lower affinity than CX3CL1. We determined an apparent binding affinity (IC 50 ) of 1.9 nM (Log IC 50 ϭ-8.73Ϯ0.21 based on three independent experiments) for F1, which is ϳ12ϫ weaker than that for CX3CL1 (IC 50 ϭ0.16 nM; Log IC 50 ϭ-9.79Ϯ0.28; Fig. 2A) . A similar difference in affinity was apparent when F1 and CX3CL1 were tested on CHO-CX3CR1 or murine RAW 264.7 cells (data not shown) and when the affinity of CX3CL1-Ig was compared with that of F1-Ig (data not shown). Together, our data confirm that the F1 analog binds specifically to CX3CR1, albeit with a slightly weaker affinity than native CX3CL1.
Our phage-selection strategy was devised to preferentially select clones that are not internalized into CX3CR1-expressing cells. Unlike native CX3CL1, which induced dose-dependent downmodulation of CX3CR1, F1 did not induce CX3CR1 internalization on HEK cells: Although 0.1 M CX3CL1 induced 40% CX3CR1 internalization after 30 min incubation (Fig. 2B , filled bars), 1 M F1 had no internalizing effect (Fig. 2B, open bars) . A similar result was obtained with CHO-CX3CR1 cells (data not shown). Up-regulating activity was even observed, as reported with CCR5 antagonists [31, 49] . This might be a result of the receptor's own intrinsic activity [49, 50] , which might be inhibited by F1, here functioning as an inverse agonist. 
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a Symbols: X represents any of the amino acids; Z represents L, P, Q, or R; ⌺ represents V, A, D, or G; ⌽ represents L, M, or V; and ⌿ represents S, P, T, or A.
F1 antagonizes CX3CL1-induced calcium and chemotactic responses
The ability of F1 to elicit calcium response in HEK-CX3CR1 cells was then compared with that of CX3CL1. In contrast to native CX3CL1, no significant response to F1 was observed up to concentrations of 300 nM in HEK-CX3CR1 cells (Fig. 3A, compare traces a and b) or 400 nM in human PBMC (Fig. 3A , compare traces c and d) and in CHO-CX3CR1 cells (data not shown). Similar results were obtained with the F1-Ig chimera (data not shown). We next tested the ability of F1 to inhibit CX3CL1-induced cellular responses. In the presence of F1 and F1-Ig, the calcium response induced by 20 nM CX3CL1 decreased dose-dependently (Fig. 3B) , with an IC 50 of 34 nM and 72 nM, respectively.
We then investigated the effect of F1 and F1-Ig on CX3CR1-mediated chemotaxis (Fig. 4) . CX3CL1 elicited significant responses in CD8ϩ T cells and NK cells (Fig. 4, A and B, f) , and CX3CL1-Ig induced chemotaxis with full efficacy but reduced potency (Fig. 4, A and B, e) , consistently with its binding affinity (data not shown) and with work published previously [43] . In contrast, neither F1 nor F1-Ig induced chemotaxis at any concentration tested (Fig. 4, A and B, triangles) . None of the ligands tested induced any detectable chemotaxis by CD4ϩ T cells (Fig.  4C) , which do not, except for the minute Th1 cytotoxic subpopulation, express CX3CR1 [4, [51] [52] [53] .
F1 and F1-Ig inhibited CX3CL1-and CX3CL1-Ig-induced chemotaxis of NK cells and of CD8ϩ T cells (Fig. 4D and (Table 2) . Hence, F1 appears to be an efficient antagonist of hCX3CR1 and mCX3CR1 receptors, as a soluble chemokine domain and as an Ig-fusion protein.
F1 antagonizes CX3CL1-mediated adhesion
The complete CX3CL1 molecule, comprising the chemokine domain linked to the cell surface via a mucin stalk, has substantial adhesive properties when paired with its receptor CX3CR1 [4 -6] . As the adhesiveness of CX3CL1 is reported to be independent of the nature of the stalk [54] , we hypothesized that CX3CL1-Ig might behave as an adhesion molecule. In a static adhesion assay, CX3CL1-Ig captured HEK-CX3CR1 cells significantly (Fig. 5A, e) , and nonspecific Ig did not (data not shown). Moreover, parental HEK cells did not adhere to CX3CL1-Ig. F1-Ig also captured CX3CR1-expressing cells specifically (Fig. 5A , ‚), albeit with an apparent potency one-eighth that of CX3CL1-Ig, consistent with its lower binding affinity ( Fig. 2A) .
Moreover, soluble F1 (Fig. 5B, OE) decreased the adhesion of CX3CR1-positive cells substantially to immobilized CX3CL1: Inhibition efficacy was 40ϫ times lower than that of sCX3CL1 (Fig.  5B, f) . Thus, F1 also antagonized the CX3CL1/CX3CR1-mediated cell adhesion. Our results also indicate that the antagonist potency of F1 differs slightly in binding ( Fig. 2A) and in adhesion (Fig. 5B ) assays.
F1 acts as an in vivo CX3CR1 antagonist
The in vivo inhibitory action of F1 was evaluated further in a noninfectious peritonitis model [55] . Three days after i.p. injection of thioglycollate, leukocytes recruited into the peritoneal cavity were analyzed by flow cytometry for their expression of macrophage markers. The CX3CL1 analogs were injected 14 h after thioglycollate injection to mimic a potential therapeutic intervention in severe inflammatory conditions. The accumulation of monocyte/macrophages (CD11b ϩ Ly6G -7/4 hi F4/ 80 hi ) was strongly inhibited after treatment with 50 g F1 and 25 g F1-Ig (70% and 95% inhibition respectively, Fig. 6A ). F1 and F1-Ig administration also inhibited recruitment of PMN (CD11b ϩ Ly6G ϩ 7/4 -F4/80 -), albeit to a lesser extent (60% and 40%, respectively, Fig. 6B ). These data demonstrate the in vivo efficacy of F1 and F1-Ig in a murine model of inflammation.
DISCUSSION
In this study, we used a phage-display strategy to select antagonistic CX3CL1 chemokine analogs, i.e., ligands able to bind the CX3CR1 receptor without triggering agonist-induced signaling. We selected and described a CX3CL1 analog that bound to CX3CR1 ( Figs. 2A and 5A ) and that did not induce any CX3CR1 internalization (Fig. 2B) or any calcium (Fig. 3A) or chemotactic (Fig. 4, A and B , and Table 2 ) responses. Moreover, F1 inhibited CX3CL1-induced calcium responses (Fig. 3B) , as well as the chemotactic (Fig. 4D and Table 2 ) and adhesive functions (Fig. 5B ) mediated by the CX3CL1-CX3CR1 axis. Finally, F1 promoted significant inhibition of monocyte/macrophage recruitment in an in vivo model of inflammation (Fig. 6) . It therefore represents a bona fide antagonist of hCX3CR1.
Several authors have reported N-terminal modifications to CX3CL1 that result in proteins with reduced agonistic properties [29] . Inoue et al. [24] reported that a mCX3CL1, lacking the four N-terminal residues, behaves as an antagonist for mCX3CR1 in vitro and in vivo. However, there is no indication that this compound also binds hCX3CR1. Moreover, removal of the first seven residues of hCX3CL1 has been shown to produce an inactive analog with poor affinity for CX3CR1 [29] . Like F1, most of the chemokine variants we selected bore the N-terminal consensus motif ILD, corresponding to residues 0, 1, and 2 of the native protein (residue 0 representing the N-terminal extension; Table 1 ). This motif is more hydrophobic than the QHHGVT sequence of the native CX3CL1, as a result of the presence of the aliphatic I and L residues, and also more acidic (D vs. H). On the other hand, there was no obvious selection at position 3, and the residues selected at positions 4 -6 resembled those found in hCX3CL1 and mCX3CL1 (Table 1) . It is therefore likely that the ILD motif at the extended N terminus of the protein plays a key role in the antagonistic properties of F1. Several other examples of N-terminally modified chemokines with altered signaling activity have been described [56] .
The F1 analog has an apparent affinity for CX3CR1 similar to that of the antagonist described previously [24] and to that of Met-RANTES for CCR5 [57] . It antagonized the chemotaxis mediated by 1 nM CX3CL1 with an apparent affinity of 3-6 nM (Fig. 4D) . It also consistently inhibited the calcium response mediated by 20 nM CX3CL1 with an apparent affinity of 34 nM (Fig. 3B ). Yet, the apparent F1 affinity in the cell adhesion assay was close to 150 nM, which is 40ϫ weaker than that of sCX3CL1 (Fig. 5B ). This indicates that the effect of F1 on cell avidity for immobilized CX3CL1 was very different from its binding affinity for CX3CR1 (Fig. 5B) and that more complex processes are probably involved in CX3CL1/CX3CR1 adhesion, compared with simple CX3CL1/CX3CR1 binding. Through further use of the phage-display strategy, it should nonetheless be possible to obtain antagonists with improved binding affinity with techniques analogous to those applied successfully with peptide libraries for "affinity maturation" [35, 37] .
Two major monocyte populations have been described in mice, varying according to the expression levels of CX3CR1 and Ly6C [58 -60] . Classical monocytes are reported to be recruited rapidly to inflammation sites, independently of CX3CR1 expression [62] . Less is known about nonclassical monocytes, but it has been suggested that they use CX3CR1 to migrate into noninflamed tissue [58, 63, 64] . Recent reports indicate that this monocyte subpopulation patrols the luminal surface of vessels and infiltrates the tissues rapidly to differentiate into macrophages, and classical monocytes reach the inflammatory site later and give rise to inflammatory dendritic cells [65] . Although monocyte/macrophage peritonitis in response to i.p. thioglycollate was not altered significantly in CX3CR1 -/-mice [62, 66] , we found here that the peritoneal macrophage population decreased dramatically after F1 or F1-Ig injections (Fig. 6A) . This indicates that F1 and F1-Ig strongly inhibit monocyte/macrophage recruitment in vivo.
Depending on dose of proteins injected into mouse peritoneum and their m.w., the inhibitory efficacy of F1-Ig (i.e., 25 g with 35 kDa m.w.) appeared to be about seven times higher than that of F1 (i.e., 50 g with 10 kDa m.w.). This can be, in part, explained by the longer in vivo half-life of the molecule provided by the Fc domain [41] (data not shown). In our in vivo experimental conditions, PMN recruitment also decreased after F1 or F1-Ig injection, although to a lesser extent than monocyte infiltration (Fig. 6B) . Although PMN expressed CX3CR1 slightly [67, 68] , we did not observe any CX3CL1-dependent chemotactic response by peritoneal PMN harvested after the thioglycollate administration (data not shown). However, macrophage-secreted inflammatory cytokines and chemokines trigger a second step of PMN recruitment during thioglycollateinduced inflammation [69, 70] , and this late wave is probably reduced strongly by the inhibition of the early phase of monocyte recruitment. This might explain the substantial effect of F1 and F1-Ig on in vivo PMN recruitment.
Our finding here that the CX3CR1 antagonist F1 strongly decreased the migration of the CX3CR1-positive monocytic population suggests that antagonists such as F1 might be useful in a thorough analysis of inflammation pathways and in a therapeutic setting, in the ultimate prevention of the side-effects of broad-spectrum inhibitors.
Selective CX3CR1 inhibitors such as F1 may eventually prove valuable in controlling inflammation in the various diseases in which CX3CL1 plays a role [7, 23, 24, 51, [71] [72] [73] . Nevertheless, it is important to direct the action of any CX3CR1 antago- nist to the inflamed organ. In atherogenesis [71] or glomerulonephritis [23] , we might anticipate that the antagonist would target the circulating and infiltrating monocytes primarily and that the resident cells would be inaccessible. Alternatively, specific targeting might be obtained by using the bivalent Ig-chimera. Hence, one antibody specific for the cell marker could be fused to the antagonistic molecule [74, 75] . Therapeutic development of CX3CR1 antagonists must be investigated cautiously, however, as CX3CL1 has a number of important physiological roles, including induction of antitumor activity [38, 76] and protection against neurodegenerative disorders [14, 15] . 
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